Author:
Okera M,Chan S,Dernede U,Larkin J,Popat S,Gilbert D,Jones L,Osuji N,Sykes H,Oakley C,Pickering L,Lofts F,Chowdhury S
Publisher
Springer Science and Business Media LLC
Reference32 articles.
1. Aapro MS, Cameron DA, Pettengell R, Bohlius J, Crawford J, Ellis M, Kearney N, Lyman GH, Tjan-Heijnen VC, Walewski J, Weber DC, Zielinski C (2006) EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 42: 2433–2453
2. Chirivella I, Bermejo B, Insa A, Perez-Fidalgo A, Magro A, Rosello S, Garcia-Garre E, Martin P, Bosch A, Lluch A (2006) Impact of chemotherapy dose-related factors on survival in breast cancer patients treated with adjuvant anthracycline-based chemotherapy. J Clin Oncol ASCO Annual Meeting Proceedings Part I. Vol 24, No 18S (June 20 Supplement), 2006: 668
3. Clamp AR, Ryder WD, Bhattacharya S, Pettengell R, Radford JA (2008) Patterns of mortality after prolonged follow-up of a randomised controlled trial using granulocyte colony-stimulating factor to maintain chemotherapy dose intensity in non-Hodgkin′s lymphoma. Br J Cancer 99: 253–258
4. Clark OA, Lyman GH, Castro AA, Clark LG, Djulbegovic B (2005) Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol 23: 4198–4214
5. Crawford J, Dale DC, Lyman GH (2004) Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer 100: 228–237